Aqualung Therapeutics Corporation To Present New Data At Biotech Showcase Investor Conference

Thursday, December 5, 2019 Press Release
Email Print This Page Comment bookmark
Font : A-A+

Aqualung, "ALT", will present new DATA on eNamptor™, a humanized monoclonal antibody (mAb) designed to limit activation of evolutionary inflammatory networks and to reduce mortality in serious inflammatory disorders, including ARDS.

TUCSON, Ariz., Dec. 5, 2019 /PRNewswire/ --ARDS (Acute Respiratory Distress Syndrome) represents ~488K US cases/yr; with >30% mortality from a highly inflammatory lung disorder without FDA-approved drugs. The anticipated U.S. market is $2.8B.

ALT was awarded a $1.7M NIH Fast Track STTR Phase I/II grant (June 2019) providing funds to complete pharmacodynamics, pharmacology and toxicology milestones for the initial indication of ARDS and ventilator-induced lung injury. A $3M Dept of Defense award is pending for trauma-induced ARDS.

The company will present to investors at the Biotech Showcase, January 13-15 in San Francisco. The company will deliver data updates and projections on its lead drug eNamptor™, a potent neutralizing mAb of eNAMPT (nicotinamide phosphoribosyltransferase) and the near and long term milestones of clinical development.

"We are excited to update potential investors and strategic partners on Aqualung's platform technology & development pipeline. With the support of several non-diluting NIH STTR awards, we have made tremendous progress with our lead biologic eNamptor™ over the last 12 months and are currently moving into IND-enabling studies to be completed by late 2020 or early 2021," said Joe "Skip" Garcia M.D., CEO of Aqualung Therapeutics.  "This presentation will add to the growing body of compelling pre-clinical evidence with eNamptor™ in the treatment of Acute Lung Injury as well as chronic conditions such as Radiation-Induced Lung Injury."

Biotech Showcase Presentation:

Date: Tuesday, January 14, 2020Time: 9:00AMTrack: Franciscan B (Ballroom Level)Location:  Hilton Hotel, Downtown San Francisco

The company presentation will be available through the Biotech Showcase website.  Following the meeting, the presentation will be available on the company website.

About Aqualung Therapeutics Corporation

Aqualung is an early stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung, and systemic inflammation. Incorporated in 2016 and led by a physician scientist, Aqualung's science-driven approach led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases.  The pipeline of ALT is designed to help in a range of diseases characterized by unchecked local and systemic inflammation: Acute Respiratory Distress Syndrome (ARDS), Ventilator- and Radiation-Induced Lung Injuries, Prostate Cancer, Pulmonary Hypertension, Pulmonary Fibrosis and Chorioamnionitis.  These conditions have a significant unmet medical need and many exhibit significant morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.

Cision View original content:http://www.prnewswire.com/news-releases/aqualung-therapeutics-corporation-to-present-new-data-at-biotech-showcase-investor-conference-300969567.html

SOURCE Aqualung Therapeutics Corporation



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store